International Edition
Latest News
Health

Needle-Free Strep A Vaccine Shows Promise in Mouse Study

A vaccine delivered through the nose or under the tongue generated strong immune responses at the mucosal surfaces where group A streptococcus first takes hold, according to a study published October 19 in Human Vaccines & Immunotherapeutics. The…

Needle-Free Strep A Vaccine Shows Promise in Mouse Study

A vaccine delivered through the nose or under the tongue generated strong immune responses at the mucosal surfaces where group A streptococcus first takes hold, according to a study published October 19 in Human Vaccines & Immunotherapeutics.

The research, led by the Medicines and Healthcare products Regulatory Agency (MHRA) with the GSK Vaccines Institute for Global Health, tested a glycoconjugate vaccine built on generalized modules for membrane antigens (GMMA) — tiny bubbles naturally shed by bacteria that serve as both carrier and adjuvant.

“This research highlights the potential of GMMA technology to support a new generation of affordable, needle-free vaccines,” said Fatme Mawas, head of conjugate vaccines at the MHRA. “By delivering a Strep A vaccine through the nose or under the tongue, we showed that strong immune responses were generated both at the mucosal surfaces where infection begins and throughout the body, supporting protection against invasive disease.”

Unlike most vaccine approaches that focus on antibodies in the bloodstream, this strategy targets immunity in the nose and throat, where Strep A establishes infection, while also inducing a broader systemic response, the study authors wrote. The work was conducted in a pre-clinical mouse model.

Global burden and the need for a vaccine

Group A streptococcus (Strep A) causes more than 600 million infections worldwide each year, with complications responsible for over 500,000 deaths annually, according to figures cited by the MHRA. There is currently no licensed vaccine.

While most infections are mild — causing sore throat or scarlet fever — invasive disease can lead to long-term disability or death, particularly in low- and middle-income countries where the burden is greatest. Rheumatic heart disease remains a major long-term consequence.

“This approach could make vaccines easier to administer and more accessible globally, particularly in low- and middle-income countries where the burden of Strep A disease is greatest,” Mawas said. “By preventing infections before they occur, vaccines can also help reduce antibiotic use and support efforts to tackle antimicrobial resistance.”

How the GMMA platform works

GMMA are outer membrane vesicles released by Gram-negative bacteria. In this study, researchers engineered GMMA to display the Strep A carbohydrate antigen, creating a glycoconjugate vaccine that does not require separate chemical conjugation or an added adjuvant.

The vaccine was administered intranasally and sublingually in mice. Both routes produced strong mucosal IgA and systemic IgG responses, the paper shows. The findings support further development of affordable, easily administered mucosal vaccines that could improve access to immunization worldwide.

Study authors journal publication MHRA research programme

The paper, “GMMA as adjuvant and carrier for mucosal delivery of group A streptococcus glycoconjugate vaccine,” was authored by James Ozanne, Manolya Saydam, Elena Palmieri and eight colleagues from the MHRA and GSK Vaccines Institute for Global Health Srl. It appears in Human Vaccines & Immunotherapeutics, volume 22, article 2740963 (DOI: 10.1080/21645515.2026.2740963).

“This work was conducted in a mouse (pre-clinical) model and forms part of the MHRA’s wider programme of research into vaccine science, immunology, assay development and novel vaccine delivery technologies,” the agency said.

Why mucosal delivery matters

Needle-free administration could lower barriers to vaccination in resource-limited settings by eliminating the need for trained injectors, cold-chain logistics for certain formulations, and sharps disposal. Mucosal vaccines also mimic the natural route of infection, potentially blocking transmission at the portal of entry.

The MHRA emphasized that the research remains pre-clinical.

“By delivering a Strep A vaccine through the nose or under the tongue, we showed that strong immune responses were generated both at the mucosal surfaces where infection begins and throughout the body, supporting protection against invasive disease.”

— Fatme Mawas, Head of Conjugate Vaccines, MHRA

Fatme Mawas

Strep a vaccine availability GMMA technology needle-free delivery

Is a Strep a vaccine available now?

No. There is currently no licensed vaccine for group A streptococcus. This study is pre-clinical, conducted in mice, and further development is needed before human trials can begin.

What is GMMA technology?

Generalized modules for membrane antigens (GMMA) are tiny vesicles naturally shed by bacteria. In this vaccine, they act as both the carrier for the Strep A carbohydrate antigen and an adjuvant to boost the immune response, simplifying manufacturing.

How would a needle-free vaccine be given?

The study tested intranasal (through the nose) and sublingual (under the tongue) delivery. Both routes generated strong mucosal and systemic immune responses in mice.

The GSK Vaccines Institute for Global Health in Siena, Italy, leads GSK’s vaccine portfolio focused on preventing enteric and diarrhoeal diseases and explores novel technologies such as GMMA for lower-income countries.

Its scientists led the development of a typhoid conjugate vaccine that was licensed to Biological E in January 2020, obtained WHO prequalification in December 2020, and began rolling out in Nepal in 2022, reaching over 7m children when introduced into its routine childhood vaccination programme.

Why target mucosal immunity?

Strep A infects the throat and nasal passages. A mucosal vaccine aims to stop the bacterium at the site of entry, potentially preventing colonization and transmission, while also producing antibodies that circulate in the bloodstream to protect against invasive disease.

About the author: Health Desk

Health Desk at Archynewsy.